Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

ObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 pa...

Full description

Bibliographic Details
Main Authors:	Xiaoxu Fang, Yan Xiang, Kaihua Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Oncology
Subjects:	almonertinib non-small cell lung cancer epidermal growth factor receptor mutation chemotherapy safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full

Similar Items

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023-10-01)

Development and Validation of a UHPLC–MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib
by: Peng-fei Tang, et al.
Published: (2022-07-01)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021-05-01)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
by: Faisal A. Almalki, et al.
Published: (2021-10-01)

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
by: Yuhai Zhang, et al.
Published: (2022-11-01)

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway
by: Chen Shi, et al.
Published: (2024-03-01)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
by: Hai Pan, et al.
Published: (2023-05-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
by: Lucheng ZHU, et al.
Published: (2021-05-01)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
by: Yuhan Zhang, et al.
Published: (2021-09-01)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
by: Gang Shen, et al.
Published: (2021-12-01)

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
by: XU Wenwen, et al.
Published: (2021-12-01)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
by: Yaping Long, et al.
Published: (2022-02-01)

Epidermal Growth Factor Receptor Mutations and Radiotherapy  in Non-small Cell Lung Cancer
by: Xing ZHONG, et al.
Published: (2013-03-01)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
by: Seung Sook Paik, M.D., et al.
Published: (2018-04-01)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
by: Renxian Xie, et al.
Published: (2023-09-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
by: Wu P, et al.
Published: (2018-10-01)

Napsin A and Thyroid Transcription Factor-1-Positive Cerebellar Tumor with Epidermal Growth Factor Receptor Mutation
by: Taiji Kuwata, et al.
Published: (2011-12-01)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
by: Chen Chen, et al.
Published: (2020-03-01)

The clinical outcome of brain metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation- A retrospective single-institution analysis
by: Cho-Hao Lee, et al.
Published: (2018-01-01)

Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum]
by: Wu P, et al.
Published: (2024-01-01)

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
by: Sang Hwa Lee, et al.
Published: (2015-11-01)

Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis
by: Anuradha Chougule, et al.
Published: (2020-01-01)

Mutations in the exons of epidermal growth factor receptor gene are associated with clinicopathological features of lung cancer
by: Yanhui Wan, et al.
Published: (2020-10-01)

Konjenital yaygın epidermal nevüs
by: Tugay TEPE, et al.
Published: (2018-12-01)

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions
by: Ping Yue, et al.
Published: (2024-03-01)

Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study
by: Yinkui Wang, et al.
Published: (2022-12-01)

Frequency and Prognosis of Epidermal Growth Factor Receptor Variant III Mutations in Glioblastoma Multiforme among Indian Patients: A Single-Institution Study
by: Wesley Mannirathil Jose, et al.
Published: (2020-07-01)

Primary Tumor Resection Plus Chemotherapy versus Chemotherapy Alone for Colorectal Cancer Patients with Synchronous Bone Metastasis
by: Yanqing Li, et al.
Published: (2023-07-01)

Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Chaoyu HONG, et al.
Published: (2016-12-01)

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review
by: Anita Brouns, et al.
Published: (2021-06-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population
by: Gaye Güler Tezel, et al.
Published: (2017-12-01)

Case Report: Sequential postzygotic HRAS mutation and gains of the paternal chromosome 11 carrying the mutated allele in a patient with epidermal nevus and rhabdomyosarcoma: evidence of a multiple-hit mechanism involving HRAS in oncogenic transformation
by: Roberta Zuntini, et al.
Published: (2023-08-01)

Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity
by: Tamilselvi Elango, et al.
Published: (2018-05-01)